中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | diphenyl (1-(N-tert-butoxycarbonylamino)-2-phenyl)ethylphosphonate | 289506-28-1 | C25H28NO5P | 453.475 |
—— | benzyl (1-(diphenoxyphosphoryl)-2-phenylethyl)carbamate | 132372-70-4 | C28H26NO5P | 487.492 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | ethyl,4-ethenylphenyl 1-amino-2-phenylethylphosphonate | —— | C18H22NO3P | 331.351 |
—— | diphenyl (1-(N-tert-butoxycarbonylamino)-2-phenyl)ethylphosphonate | 289506-28-1 | C25H28NO5P | 453.475 |
—— | ethyl,4-ethenylphenyl (1-(N-tert-butoxycarbonylamino)-2-phenyl)ethylphosphonate | 289506-30-5 | C23H30NO5P | 431.469 |
—— | S-ethyl,4-ethenylphenyl (1-(N-tert-butoxycarbonylamino)-2-phenyl)ethylphosphonate | —— | C23H30NO5P | 431.469 |
Enzyme specific inhibitors can be designed based on endogenous substrate peptide motifs and modified to yield specific activity-based probes (ABPs). The development/validation of a theranostic ABP-inhibitor prototype for KLK7 protease is presented.